Archive - March 2018
Bristol-Myers Squibb’s Opdivo (nivolumab) Now the First and Only FDA-Approved PD-1 Inhibitor to Offer Every Four-Week Dosing
Consumers hungry for more digital healthcare interaction
Bright Screens Before Bedtime Can Disrupt Sleep For Preschoolers
News from Abroad — Australia Remains a Gene-Patent Friendly Jurisdiction
Federal appeals court stalls CSR lawsuit settlement
Tenet again lowers threshold for investors to call meetings
News from other sources
OneKey Releases Top Medical Group Parent Report